» Articles » PMID: 11489940

Impaired JAK-STAT Signal Transduction Contributes to Growth Hormone Resistance in Chronic Uremia

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2001 Aug 8
PMID 11489940
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic renal failure (CRF) is associated with resistance to the growth-promoting and anabolic actions of growth hormone (GH). In rats with CRF induced by partial renal ablation, 7 days of GH treatment had a diminished effect on weight gain and hepatic IGF-1 and IGFBP-1 mRNA levels, compared with sham-operated pair-fed controls. To assess whether GH resistance might be due to altered signal transduction, activation of the JAK-STAT pathway was studied 10 or 15 minutes after intravenous injection of 5 mg/kg GH or vehicle. Hepatic GH receptor (GHR) mRNA levels were significantly decreased in CRF, but GHR protein abundance and GH binding to microsomal and plasma membranes was unaltered. JAK2, STAT1, STAT3, and STAT5 protein abundance was also unchanged. However, GH-induced tyrosine phosphorylation of JAK2, STAT5, and STAT3 was 75% lower in the CRF animals. Phosphorylated STAT5 and STAT3 were also diminished in nuclear extracts. The expression of the suppressor of cytokine signaling-2 (SOCS-2) was increased twofold in GH-treated CRF animals, and SOCS-3 mRNA levels were elevated by 60% in CRF, independent of GH treatment. In conclusion, CRF causes a postreceptor defect in GH signal transduction characterized by impaired phosphorylation and nuclear translocation of GH-activated STAT proteins, which is possibly mediated, at least in part, by overexpression of SOCS proteins.

Citing Articles

Indoxyl Sulfate Contributes to Impaired Height Velocity in (Pre)School Children.

Snauwaert E, De Buyser S, Van Biesen W, Raes A, Glorieux G, Collard L Kidney Int Rep. 2024; 9(6):1674-1683.

PMID: 38899199 PMC: 11184389. DOI: 10.1016/j.ekir.2024.03.021.


Growth Hormone Treatment for Non-GHD Disorders: Excitement Tempered by Biology.

Grimberg A, Hawkes C J Clin Endocrinol Metab. 2023; 109(2):e442-e454.

PMID: 37450564 PMC: 10795916. DOI: 10.1210/clinem/dgad417.


Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice.

Benoit B, Beau A, Bres E, Chanon S, Pinteur C, Vieille-Marchiset A Sci Rep. 2023; 13(1):5520.

PMID: 37015932 PMC: 10073190. DOI: 10.1038/s41598-023-31874-4.


Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia.

Mak R, Gunta S, Oliveira E, Cheung W Int J Mol Sci. 2022; 23(23).

PMID: 36499637 PMC: 9740214. DOI: 10.3390/ijms232315310.


The Effect of Nutrition and Exercise on Body Composition, Exercise Capacity, and Physical Functioning in Advanced CKD Patients.

Ekramzadeh M, Santoro D, Kopple J Nutrients. 2022; 14(10).

PMID: 35631270 PMC: 9143955. DOI: 10.3390/nu14102129.


References
1.
Mao Y, Ling P, Fitzgibbons T, McCowen K, Frick G, Bistrian B . Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo. Endocrinology. 1999; 140(12):5505-15. DOI: 10.1210/endo.140.12.7212. View

2.
Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I . Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol. 1999; 19(9):6396-407. PMC: 84609. DOI: 10.1128/MCB.19.9.6396. View

3.
Boisclair Y, Wang J, Shi J, Hurst K, Ooi G . Role of the suppressor of cytokine signaling-3 in mediating the inhibitory effects of interleukin-1beta on the growth hormone-dependent transcription of the acid-labile subunit gene in liver cells. J Biol Chem. 2000; 275(6):3841-7. DOI: 10.1074/jbc.275.6.3841. View

4.
Kaysen G . Inflammation nutritional state and outcome in end stage renal disease. Miner Electrolyte Metab. 2000; 25(4-6):242-50. DOI: 10.1159/000057455. View

5.
Touw I, de Koning J, Ward A, Hermans M . Signaling mechanisms of cytokine receptors and their perturbances in disease. Mol Cell Endocrinol. 2000; 160(1-2):1-9. DOI: 10.1016/s0303-7207(99)00206-3. View